Representative Thomas H. Kean, Jr. (Republican-New Jersey) recently sold shares of Stryker Corporation (NYSE:SYK). In a filing disclosed on November 19th, the Representative disclosed that they had sold between $1,001 and $15,000 in Stryker stock on October 27th. The trade occurred in the Representative’s “STATE STREET BANK & TRUST CO.” account.
Representative Thomas H. Kean, Jr. also recently made the following trade(s):
- Sold $1,001 – $15,000 in shares of Johnson & Johnson (NYSE:JNJ) on 10/27/2026.
- Sold $15,001 – $50,000 in shares of Microsoft (NASDAQ:MSFT) on 10/27/2026.
- Sold $1,001 – $15,000 in shares of Warner Bros. Discovery (NASDAQ:WBD) on 10/7/2026.
- Sold $1,001 – $15,000 in shares of Stryker (NYSE:SYK) on 9/30/2026.
- Sold $1,001 – $15,000 in shares of Johnson & Johnson (NYSE:JNJ) on 9/30/2026.
- Purchased $1,001 – $15,000 in shares of ESAB (NYSE:ESAB) on 9/29/2026.
- Sold $1,001 – $15,000 in shares of Mondelez International (NASDAQ:MDLZ) on 9/23/2026.
- Sold $1,001 – $15,000 in shares of Abbott Laboratories (NYSE:ABT) on 9/17/2026.
- Purchased $1,001 – $15,000 in shares of Texas Instruments (NASDAQ:TXN) on 9/17/2026.
- Sold $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 8/27/2026.
Stryker Price Performance
SYK stock opened at $309.91 on Friday. The company has a quick ratio of 1.30, a current ratio of 2.18 and a debt-to-equity ratio of 0.60. The firm has a market cap of $117.98 billion, a price-to-earnings ratio of 33.00, a PEG ratio of 2.13 and a beta of 0.78. The company’s fifty day simple moving average is $295.66 and its 200 day simple moving average is $321.39. Stryker Corporation has a 12-month low of $267.00 and a 12-month high of $389.33.
Stryker (NYSE:SYK – Get Free Report) last issued its earnings results on Thursday, October 29th. The medical technology company reported $3.52 earnings per share for the quarter, missing analysts’ consensus estimates of $3.55 by ($0.03). Stryker had a return on equity of 23.74% and a net margin of 13.78%. The business had revenue of $6.52 billion during the quarter, compared to the consensus estimate of $6.62 billion. During the same quarter in the previous year, the firm posted $3.19 earnings per share. The company’s revenue for the quarter was up 7.6% compared to the same quarter last year. On average, analysts expect that Stryker Corporation will post 14.85 earnings per share for the current year.
Wall Street Analyst Weigh In
SYK has been the subject of a number of analyst reports. Sanford C. Bernstein reiterated a “market perform” rating on shares of Stryker in a research note on Wednesday, October 7th. BMO Capital Markets reiterated an “outperform” rating and issued a $309.00 target price (down from $317.00) on shares of Stryker in a report on Friday, October 30th. Wolfe Research lowered shares of Stryker from an “outperform” rating to a “peer perform” rating in a research report on Thursday, August 13th. Wall Street Zen cut shares of Stryker from a “buy” rating to a “hold” rating in a report on Saturday, October 3rd. Finally, Truist Financial reaffirmed a “hold” rating and issued a $305.00 price objective (down from $310.00) on shares of Stryker in a research report on Monday, November 2nd. Twenty-one analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Stryker currently has a consensus rating of “Moderate Buy” and an average target price of $343.77.
View Our Latest Analysis on SYK
Insider Transactions at Stryker
In other Stryker news, Director Ronda Stryker sold 550,000 shares of Stryker stock in a transaction dated Friday, November 6th. The stock was sold at an average price of $325.32, for a total transaction of $178,926,000.00. Following the completion of the sale, the director owned 1,701,375 shares of the company’s stock, valued at $553,491,315. The trade was a 24.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 4.60% of the stock is currently owned by insiders.
Institutional Investors Weigh In On Stryker
Several large investors have recently made changes to their positions in the business. State Street Corp raised its position in shares of Stryker by 1.2% in the second quarter. State Street Corp now owns 15,532,565 shares of the medical technology company’s stock worth $4,903,772,000 after buying an additional 183,400 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of Stryker by 0.6% during the 2nd quarter. Wellington Management Group LLP now owns 8,167,185 shares of the medical technology company’s stock valued at $2,571,357,000 after acquiring an additional 45,478 shares during the last quarter. Bank of America Corp DE bought a new position in shares of Stryker in the second quarter worth approximately $1,404,284,000. Royal Bank of Canada increased its position in shares of Stryker by 6.5% in the first quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company’s stock worth $1,075,552,000 after purchasing an additional 199,863 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Stryker by 21.8% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,689,376 shares of the medical technology company’s stock valued at $846,723,000 after purchasing an additional 481,175 shares in the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.
About Representative Kean
Thomas Kean Jr. (Republican Party) is a member of the U.S. House, representing New Jersey’s 7th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.
Kean (Republican Party) is running for re-election to the U.S. House to represent New Jersey’s 7th Congressional District. He declared candidacy for the 2026 election.
Thomas Kean Jr. lives in Westfield, New Jersey. Kean earned a master’s degree from the Tufts University Fletcher School of Law and Diplomacy. His career experience includes working with the Environmental Protection Agency during the George H.W. Bush administration and as an advisor to former U.S. Representative Bob Franks, a firefighter, and an emergency medical technician. Kean has served as the vice president of a fire department.
Stryker Company Profile
Stryker is a medical technology company that develops and sells products and services for healthcare providers. Its offerings include orthopedic implants and surgical equipment, neurotechnology and spine products, and medical and surgical equipment used in hospitals and other care settings. The company’s products also include patient-handling and emergency medical equipment, as well as instruments and technologies that support surgical procedures. Stryker serves healthcare customers in the United States and internationally.
Read More
- Five stocks we like better than Stryker
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.
